Generation of isogenic pluripotent stem cells differing exclusively at two early onset parkinson point mutations

Frank Soldner, Josée Laganière, Albert W. Cheng, Dirk Hockemeyer, Qing Gao, Raaji Alagappan, Vikram Khurana, Lawrence I. Golbe, Richard H. Myers, Susan Lindquist, Lei Zhang, Dmitry Guschin, Lauren K. Fong, B. Joseph Vu, Xiangdong Meng, Fyodor D. Urnov, Edward J. Rebar, Philip D. Gregory, H. Steve Zhang, Rudolf Jaenisch

Research output: Contribution to journalArticle

492 Citations (Scopus)

Abstract

Patient-specific induced pluripotent stem cells (iPSCs) derived from somatic cells provide a unique tool for the study of human disease, as well as a promising source for cell replacement therapies. One crucial limitation has been the inability to perform experiments under genetically defined conditions. This is particularly relevant for late age onset disorders in which in vitro phenotypes are predicted to be subtle and susceptible to significant effects of genetic background variations. By combining zinc finger nuclease (ZFN)-mediated genome editing and iPSC technology, we provide a generally applicable solution to this problem, generating sets of isogenic disease and control human pluripotent stem cells that differ exclusively at either of two susceptibility variants for Parkinson's disease by modifying the underlying point mutations in the α-synuclein gene. The robust capability to genetically correct disease-causing point mutations in patient-derived hiPSCs represents significant progress for basic biomedical research and an advance toward hiPSC-based cell replacement therapies.

Original languageEnglish (US)
Pages (from-to)318-331
Number of pages14
JournalCell
Volume146
Issue number2
DOIs
StatePublished - Jul 22 2011
Externally publishedYes

Fingerprint

Induced Pluripotent Stem Cells
Pluripotent Stem Cells
Stem cells
Point Mutation
Cell- and Tissue-Based Therapy
Synucleins
Genes
Zinc Fingers
Age of Onset
Parkinson Disease
Biomedical Research
Technology
Phenotype
Zinc
Experiments

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Soldner, F., Laganière, J., Cheng, A. W., Hockemeyer, D., Gao, Q., Alagappan, R., ... Jaenisch, R. (2011). Generation of isogenic pluripotent stem cells differing exclusively at two early onset parkinson point mutations. Cell, 146(2), 318-331. https://doi.org/10.1016/j.cell.2011.06.019

Generation of isogenic pluripotent stem cells differing exclusively at two early onset parkinson point mutations. / Soldner, Frank; Laganière, Josée; Cheng, Albert W.; Hockemeyer, Dirk; Gao, Qing; Alagappan, Raaji; Khurana, Vikram; Golbe, Lawrence I.; Myers, Richard H.; Lindquist, Susan; Zhang, Lei; Guschin, Dmitry; Fong, Lauren K.; Vu, B. Joseph; Meng, Xiangdong; Urnov, Fyodor D.; Rebar, Edward J.; Gregory, Philip D.; Zhang, H. Steve; Jaenisch, Rudolf.

In: Cell, Vol. 146, No. 2, 22.07.2011, p. 318-331.

Research output: Contribution to journalArticle

Soldner, F, Laganière, J, Cheng, AW, Hockemeyer, D, Gao, Q, Alagappan, R, Khurana, V, Golbe, LI, Myers, RH, Lindquist, S, Zhang, L, Guschin, D, Fong, LK, Vu, BJ, Meng, X, Urnov, FD, Rebar, EJ, Gregory, PD, Zhang, HS & Jaenisch, R 2011, 'Generation of isogenic pluripotent stem cells differing exclusively at two early onset parkinson point mutations', Cell, vol. 146, no. 2, pp. 318-331. https://doi.org/10.1016/j.cell.2011.06.019
Soldner, Frank ; Laganière, Josée ; Cheng, Albert W. ; Hockemeyer, Dirk ; Gao, Qing ; Alagappan, Raaji ; Khurana, Vikram ; Golbe, Lawrence I. ; Myers, Richard H. ; Lindquist, Susan ; Zhang, Lei ; Guschin, Dmitry ; Fong, Lauren K. ; Vu, B. Joseph ; Meng, Xiangdong ; Urnov, Fyodor D. ; Rebar, Edward J. ; Gregory, Philip D. ; Zhang, H. Steve ; Jaenisch, Rudolf. / Generation of isogenic pluripotent stem cells differing exclusively at two early onset parkinson point mutations. In: Cell. 2011 ; Vol. 146, No. 2. pp. 318-331.
@article{707e35253a95412db171b65233db8d63,
title = "Generation of isogenic pluripotent stem cells differing exclusively at two early onset parkinson point mutations",
abstract = "Patient-specific induced pluripotent stem cells (iPSCs) derived from somatic cells provide a unique tool for the study of human disease, as well as a promising source for cell replacement therapies. One crucial limitation has been the inability to perform experiments under genetically defined conditions. This is particularly relevant for late age onset disorders in which in vitro phenotypes are predicted to be subtle and susceptible to significant effects of genetic background variations. By combining zinc finger nuclease (ZFN)-mediated genome editing and iPSC technology, we provide a generally applicable solution to this problem, generating sets of isogenic disease and control human pluripotent stem cells that differ exclusively at either of two susceptibility variants for Parkinson's disease by modifying the underlying point mutations in the α-synuclein gene. The robust capability to genetically correct disease-causing point mutations in patient-derived hiPSCs represents significant progress for basic biomedical research and an advance toward hiPSC-based cell replacement therapies.",
author = "Frank Soldner and Jos{\'e}e Lagani{\`e}re and Cheng, {Albert W.} and Dirk Hockemeyer and Qing Gao and Raaji Alagappan and Vikram Khurana and Golbe, {Lawrence I.} and Myers, {Richard H.} and Susan Lindquist and Lei Zhang and Dmitry Guschin and Fong, {Lauren K.} and Vu, {B. Joseph} and Xiangdong Meng and Urnov, {Fyodor D.} and Rebar, {Edward J.} and Gregory, {Philip D.} and Zhang, {H. Steve} and Rudolf Jaenisch",
year = "2011",
month = "7",
day = "22",
doi = "10.1016/j.cell.2011.06.019",
language = "English (US)",
volume = "146",
pages = "318--331",
journal = "Cell",
issn = "0092-8674",
publisher = "Cell Press",
number = "2",

}

TY - JOUR

T1 - Generation of isogenic pluripotent stem cells differing exclusively at two early onset parkinson point mutations

AU - Soldner, Frank

AU - Laganière, Josée

AU - Cheng, Albert W.

AU - Hockemeyer, Dirk

AU - Gao, Qing

AU - Alagappan, Raaji

AU - Khurana, Vikram

AU - Golbe, Lawrence I.

AU - Myers, Richard H.

AU - Lindquist, Susan

AU - Zhang, Lei

AU - Guschin, Dmitry

AU - Fong, Lauren K.

AU - Vu, B. Joseph

AU - Meng, Xiangdong

AU - Urnov, Fyodor D.

AU - Rebar, Edward J.

AU - Gregory, Philip D.

AU - Zhang, H. Steve

AU - Jaenisch, Rudolf

PY - 2011/7/22

Y1 - 2011/7/22

N2 - Patient-specific induced pluripotent stem cells (iPSCs) derived from somatic cells provide a unique tool for the study of human disease, as well as a promising source for cell replacement therapies. One crucial limitation has been the inability to perform experiments under genetically defined conditions. This is particularly relevant for late age onset disorders in which in vitro phenotypes are predicted to be subtle and susceptible to significant effects of genetic background variations. By combining zinc finger nuclease (ZFN)-mediated genome editing and iPSC technology, we provide a generally applicable solution to this problem, generating sets of isogenic disease and control human pluripotent stem cells that differ exclusively at either of two susceptibility variants for Parkinson's disease by modifying the underlying point mutations in the α-synuclein gene. The robust capability to genetically correct disease-causing point mutations in patient-derived hiPSCs represents significant progress for basic biomedical research and an advance toward hiPSC-based cell replacement therapies.

AB - Patient-specific induced pluripotent stem cells (iPSCs) derived from somatic cells provide a unique tool for the study of human disease, as well as a promising source for cell replacement therapies. One crucial limitation has been the inability to perform experiments under genetically defined conditions. This is particularly relevant for late age onset disorders in which in vitro phenotypes are predicted to be subtle and susceptible to significant effects of genetic background variations. By combining zinc finger nuclease (ZFN)-mediated genome editing and iPSC technology, we provide a generally applicable solution to this problem, generating sets of isogenic disease and control human pluripotent stem cells that differ exclusively at either of two susceptibility variants for Parkinson's disease by modifying the underlying point mutations in the α-synuclein gene. The robust capability to genetically correct disease-causing point mutations in patient-derived hiPSCs represents significant progress for basic biomedical research and an advance toward hiPSC-based cell replacement therapies.

UR - http://www.scopus.com/inward/record.url?scp=79960833952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960833952&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2011.06.019

DO - 10.1016/j.cell.2011.06.019

M3 - Article

C2 - 21757228

AN - SCOPUS:79960833952

VL - 146

SP - 318

EP - 331

JO - Cell

JF - Cell

SN - 0092-8674

IS - 2

ER -